Pepdexpepdex
My Stack
№ 004

VK2735

Investigational dual agonist (GLP-1 + GIP) from Viking Therapeutics, with both a weekly injectable and a once-daily oral form in development.

Fat Loss
Evidence: Moderate

VK2735: Investigational dual agonist (GLP-1 + GIP) from Viking Therapeutics, with both a weekly injectable and a once-daily oral form in development. VK2735 is an experimental weight-loss drug from Viking Therapeutics.

FDA ⓘ
Not approved
WADA
Not banned
Typical dose
No approved human dosing
Half-life ⓘ
Long-acting; dosed once-weekly (subcutaneous) in trials
Route ⓘ
Subcutaneous (weekly) or oral (daily), both investigational
Schedule
Weekly (injectable) or once-daily (oral) in trials
In plain English

VK2735 is an experimental weight-loss drug from Viking Therapeutics. It works on two gut-hormone receptors (GLP-1 and GIP) to cut appetite, the same combo as Tirzepatide. The notable part is the pill version: in early trials a once-daily tablet got close to the results of the injection. It is still in testing and not approved.

Status & legalityWhat do these mean? →
Natty? ⓘ
Not natty
FDA ⓘ
Not approved

Investigational. The injectable is in Phase 3 (begun 2025); the oral form is expected to enter Phase 3 around late 2026. Pivotal readouts are not expected before 2027. Not approved.

Compounding ⓘ
Investigational

In clinical trials, not yet approved for prescription.

WADA ⓘ
Not listed

GLP-1/GIP agonists are not specifically named on the WADA Prohibited List, but as an unapproved investigational substance VK2735 is likely prohibited under S0 (non-approved substances) for tested athletes, so treat it as banned if you compete.

Prescribed ⓘ

Not available by prescription. Access is trial-only through Viking Therapeutics' clinical program.

Who it's for

  • →People following the oral-GLP-1 race who want a needle-free option
  • →Users tracking next-generation weight-loss compounds before approval
  • →Anyone comparing it to Tirzepatide's GLP-1/GIP mechanism

What to expect

  1. Week 1

    Trial data: appetite drops early, mild-to-moderate nausea is the most common effect at the start.

  2. Week 4

    Progressive weight loss across all doses in the Phase 2 VENTURE program.

  3. Week 8

    Loss kept building with no plateau seen by the 13-week trial endpoint.

Looking at VK2735? Your next 3 steps

  1. 1Work out your exact dose

    Vial size + BAC water turns into the exact units to draw for VK2735.

    Open calculator →
  2. 2See what to stack & monitor

    The companion supplements and the bloodwork worth tracking on this kind of protocol.

    Bloodwork guide →
  3. 3Save it & ask the Coach

    A free account saves your stack; membership adds the stack-aware AI Coach.

    Create free account →

Dosing protocol

Members only

Stacks well with

Members only

Side effects

01Nausea (most common, usually mild to moderate)
02Vomiting
03Diarrhea or constipation
04Reduced appetite strong enough to cut protein intake too far
05In the oral Phase 2, GI effects drove notable dropouts (around a quarter of participants overall, more at the highest dose)

When NOT to use

  • ⚠Class-based caution (VK2735 has no FDA label yet): personal or family history of medullary thyroid carcinoma or MEN-2
  • ⚠Class-based caution / likely trial exclusion: pancreatitis history
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • Lipid panel
  • • Liver enzymes (ALT/AST)
  • • A1C if metabolic context

Common mistakes

  • • Treating early trial data as a finished safety profile, it is Phase 2
  • • Assuming the oral form is interchangeable with the injectable, the exposure differs
  • • Sourcing an investigational compound where identity and purity cannot be verified

The Pepdex take

Pepdex take: the oral form is the part worth watching. An everyday tablet that landed near injectable results in Phase 2 is a real story for people who will never inject, though the oral arm also saw meaningful dropouts from stomach side effects at higher doses, so 'well tolerated' has an asterisk. It is dual GLP-1/GIP, the same receptor combo as Tirzepatide, not the triple-agonist route Retatrutide takes. It is investigational: the injectable is already in Phase 3 and the oral form is expected to enter Phase 3 around late 2026, with pivotal readouts not before 2027. There is no approved dosing and source quality is a real risk. Watch the data, do not treat it as a settled compound yet.
Free, no account needed

New to VK2735? Grab the starter checklist.

Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.

No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.

AI Coach, live sample
Members only
is 250mcg of bpc enough for a knee injury?
For a knee, 250 mcg sub-q daily is the standard working dose and a solid place to start. The trick with BPC is consistency, give it weeks, not days. Inject close to the joint, run it 4-6 weeks, and don't drop below 200 mcg, it tends to stop cracking the threshold reliably down there. If it hasn't moved at all by week 3, that's when adding TB-500 earns its place.
how much bac water for a 10mg reta vial?
3 mL is the standard play for a 10 mg reta vial. That's 3,333 mcg/mL, clean unit math across the titration: 2 mg = 60 units, 4 mg = 120 units, 6 mg = 180 units on a 100-unit insulin syringe. Run 2 mL instead if you want fewer, more concentrated shots (5,000 mcg/mL, so 2 mg = 40 units). Since most people titrate up over ~12 weeks, 3 mL keeps the numbers cleanest.
what should i track on bloodwork for tirzepatide?
Lipid panel, ALT/AST (liver enzymes), and an A1C, baseline before you start then every 3 months. If you've got metabolic-syndrome history, add fasting glucose and insulin so you can actually watch insulin sensitivity improve. You don't need a big hormone panel for a GLP-1.

Ask the Coach anything about VK2735 or your own stack. This is it working.

Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.

Get the Coach, $7.99/mo →

Frequently asked

What is VK2735?+
VK2735 is an experimental weight-loss drug from Viking Therapeutics. It works on two gut-hormone receptors (GLP-1 and GIP) to cut appetite, the same combo as Tirzepatide. The notable part is the pill version: in early trials a once-daily tablet got close to the results of the injection. It is still in testing and not approved.
Is VK2735 FDA approved?+
Investigational. The injectable is in Phase 3 (begun 2025); the oral form is expected to enter Phase 3 around late 2026. Pivotal readouts are not expected before 2027. Not approved.
Is VK2735 legal?+
VK2735 is not FDA-approved. It is sold by compounding pharmacies (with a prescription) and as "research only" by peptide vendors. Possession is generally not criminalized but distribution without authorization may be. Verify local laws.
Is VK2735 banned by WADA?+
VK2735 is not currently on the WADA prohibited list. GLP-1/GIP agonists are not specifically named on the WADA Prohibited List, but as an unapproved investigational substance VK2735 is likely prohibited under S0 (non-approved substances) for tested athletes, so treat it as banned if you compete.
Are you still natty after taking VK2735?+
No. VK2735 is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe VK2735?+
Not available by prescription. Access is trial-only through Viking Therapeutics' clinical program.
What's the typical dose of VK2735?+
Dosing depends on your goal, experience, and tolerance. The full VK2735 protocol (dose, frequency, and how to titrate) is in the members section on the entry page.
What are the side effects of VK2735?+
Common side effects include: Nausea (most common, usually mild to moderate); Vomiting; Diarrhea or constipation; Reduced appetite strong enough to cut protein intake too far. Less common effects and full safety details are on the entry page.
How long until VK2735 starts working?+
Trial data: appetite drops early, mild-to-moderate nausea is the most common effect at the start.
What can you stack with VK2735?+
VK2735 is commonly combined with complementary compounds. The full stacking protocol (what to pair, dosing, and timing) is in the members section on the entry page.
Where do people get VK2735?+
Pepdex does not sell, ship, or recommend suppliers. VK2735 is not FDA-approved; prescription versions require licensed clinical care, and "research only" markets carry real legal and quality risks. /coa explains how to verify a Certificate of Analysis and /guides/scam-vendor-spotting covers the red flags.
VK2735 vs Tirzepatide, which is better?+
VK2735 vs Tirzepatide: two dual GLP-1/GIP agonists on results, the oral option, and availability. Full head-to-head comparison: https://pepdex.co/compare/vk2735-vs-tirzepatide
VK2735 vs Retatrutide, which is better?+
VK2735 vs Retatrutide: dual vs triple agonist, the oral option vs the strongest trial numbers. Full head-to-head comparison: https://pepdex.co/compare/vk2735-vs-retatrutide

Head-to-head with VK2735

Compare
VK2735 vs Tirzepatide →
Compare
VK2735 vs Retatrutide →

More in Fat Loss

№ 009
Tirzepatide

Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.

№ 010
Semaglutide

The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.

№ 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

№ 059
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.